Access routes · June 2026

Compare pre-IPO access routes

econ.markets binary contracts vs the three dominant private-market secondaries — side-by-side on every dimension that matters.

Getting pre-IPO exposure looks the same from the outside: you put capital to work on a private company before it lists. The mechanics are radically different. econ.markets is a contract platform — you trade binary outcomes on-chain, with no accreditation wall and no minimum. Forge, EquityZen, and Hiive are regulated secondary marketplaces where you buy real equity (or SPV interests) with accreditation requirements, five-figure minimums, and multi-week settlement windows. Each page below makes the tradeoffs explicit with sourced figures.

econ.markets vs
Forge Global

Schwab-backed regulated broker-dealer; real equity; $100K direct minimum; 45–60 day settlement.

See full comparison →
econ.markets vs
EquityZen

Morgan Stanley-owned; lowest accredited minimum ($10K); SPV membership interests; 8–11 week settlement.

See full comparison →
econ.markets vs
Hiive

Live order-book with real bid/ask; no buyer fee on direct deals; US + Canada only; ROFR risk.

See full comparison →

What makes econ.markets different

  • No accreditation requiredTrade without meeting SEC accredited-investor thresholds.
  • No fixed minimumPosition size is the trader's choice — put in what you decide.
  • Passport-agnosticUS, Asia, and MENA supported from day one. No country-by-country compliance review.
  • Two-sided marketsLONG and SHORT contracts on every listed company — the only way to express a bearish view on a private company's IPO timeline.
  • On-chain settlementEnter or exit any time the market is open. No 45-day ROFR, no issuer approval, no lockup.
  • Contracts, not sharesBe clear on what you own: a binary contract position, not equity. econ.markets contracts are exposure instruments, not company shares.

Competitor terms change; figures sourced as of June 2026 — verify with each provider before transacting. econ.markets contracts are exposure instruments, not company shares. Nothing on this page is investment advice.